Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591595 | 0.86 | MGLL (0.42) | MGLLXDHAAK1AR | |
| SCHEMBL3599508 | 0.86 | ADRB2 (0.43) | AR | |
| SCHEMBL12128121 | 0.81 | KDM4E (0.40) | MGLLXDHAAK1ARS1PR1 | |
| SCHEMBL3586163 | 0.81 | AR (0.40) | AR | |
| SCHEMBL3585125 | 0.80 | XDH (0.38) | XDHAAK1AR | |
| SCHEMBL3589010 | 0.78 | XDH (0.47) | XDHAAK1AR | |
| SCHEMBL3584446 | 0.74 | XDH (0.46) | XDHAAK1S1PR1S1PR3S1PR5 | |
| SCHEMBL3593175 | 0.74 | NPC1 (0.41) | AR | |
| SCHEMBL3581427 | 0.74 | KDM4E (0.41) | XDHAAK1S1PR1MRGPRX4S1PR3 | |
| SCHEMBL8216484 | 0.71 | XDH (0.43) | XDHAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | MGLL 434/4885XDH 1/4885AAK1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.